Linganisha mbinu

	Muundo wa AB wa Kufungwa Macho Mara Moja	Jaribio la Kisayansi la Kidhibiti cha Machafuko lenye Kufunikwa kwa Upande Mmoja
Nyanja	Muundo wa Majaribio	Muundo wa Majaribio
Familia	Process / pipeline	Process / pipeline
Mwaka wa asili	1960s (AB methodology); blinding adaptation in single-case research developed from 1970s onward	1948 (formalized); single-blind variant established in mid-20th century clinical trial methodology
Mwanzilishi	Murray Sidman; Baer, Wolf & Risley (AB logic); blinding conventions adapted from clinical trial methodology	Bradford Hill and colleagues (MRC streptomycin trial, 1948); blinding conventions codified in CONSORT guidelines
Aina	Single-subject experimental design with assessor masking	Experimental design — blinded randomized trial
Chanzo asilia	Kazdin, A. E. (2011). Single-Case Research Designs: Methods for Clinical and Applied Settings (2nd ed.). Oxford University Press. ISBN: 9780195341881	Schulz, K. F., Altman, D. G., Moher, D., & CONSORT Group. (2010). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ, 340, c332.
Majina mbadala	assessor-blind AB design, single-masked AB single-case design, observer-blind AB phase design	single-masked RCT, single-blind RCT, single-blind trial, SB-RCT
Zinazohusiana	6	5
Muhtasari	The single-blind AB design is a single-subject experimental design that combines the two-phase AB structure — a baseline phase (A) followed by an intervention phase (B) — with assessor or observer masking. The individual collecting or rating outcome data is kept unaware of which phase is being measured, preventing knowledge of treatment status from biasing behavioral observations or ratings. The design improves on the standard AB design by reducing detection bias while retaining the practical and ethical advantages of single-subject methodology.	A single-blind randomized controlled trial (SB-RCT) is a rigorous experimental design in which participants are randomly assigned to treatment or control conditions while remaining unaware of which condition they have received. Investigators, outcome assessors, and data analysts are not blinded. By masking participants, the design eliminates placebo and nocebo response biases on the participant side, while preserving investigator flexibility to administer and monitor the intervention.